anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for purifying equine interferon beta (Eq IFN-beta) comprises: (a) inactivating E. coli host cells with acid and extracting the EqIFN-beta with an alkaline medium.  (b) precipitating the cell culture supernatant with polyethylamine and running this on an ion-exchange column and/or a molecular sieve.  (c) eluting the EqIFN-beta with a phosphate buffer; and (d) purifying the eluted interferon further using an anion and/or cation exchanger.  The extraction pH is 10 and in stage (b), adsorption on the column is achieved by the use of hydroxyapatite.  The anion-exchanger is monoQ and the cation-exchanger is Mino S.  Elution on the anion exchange column uses a linear gradient of sodium chloride.  For the cation exchange column, a linear gradient of ammonium sulphate is used. USE/ADVANTAGE - The purified EqIFN-beta is useful as an antiviral medicament and also has immunomodulatory activity.
INTRODUCTION: This study aimed to develop artificial intelligence models for predicting hip implant failure from radiological features. Analyzing the evolution of the periprosthetic bone and implant's position throughout the entire follow-up period has shown the potential to be more relevant in outcome prediction than simply considering the latest radiographic images. Thus, we investigated an AI-based model employing a small set of evolutional parameters derived from conventional radiological features to predict hip prosthesis failure.
MATERIALS AND METHODS: One hundred sixty-nine radiological features were annotated from historical anteroposterior and lateral radiographs for 162 total hip arthroplasty patients, 32 of which later underwent implant failure. Linear regression on each patient's chronologically sorted radiological features was employed to derive 169 corresponding evolutional parameters per image. Three sets of machine learning predictors were developed: one employing the original features (standard model), one the evolutional ones (evolutional model), and the last their union (hybrid model). Each set included a model employing all the available features (full model) and a model employing the few most predictive ones according to Gini importance (minimal model).
RESULTS: The evolutional and hybrid predictors resulted highly effective (area under the ROC curve (AUC) of full models = 0.94), outperforming the standard one, whose AUC was only 0.82. The minimal hybrid model, employing just four features, three of which evolutional, scored an AUC of 0.95, proving even more accurate than the full one, exploiting 173 features. This tool could be shaped to be either highly specific (sensitivity: 80%, specificity: 98.6%) or highly sensitive (sensitivity: 90%, specificity: 92.4%).
CONCLUSION: The proposed predictor may represent a highly sensitive screening tool for clinicians, capable to predict THA failure with an advance between a few months and more than a year through only four radiological parameters, considering either their value at the latest visit or their evolution through time.
We assessed the association between troponin levels and all-cause mortality in individuals with chest pain who presented to the Charleston Area Medical Center Emergency Department (CAMC). We identified adult patients with chest pain as defined in the International Classification of Diseases 10 (R07) family group from the CAMC data warehouse between June 6, 2020, and June 6, 2021. These cases required a visit to the emergency room. We created 3 different cohorts to assess the endpoints of all-cause mortality at 30 days and 6 months. Patients were divided into the following 3 categories: negative troponin level, defined as high sensitivity troponin I (HSTNI) assay ≤15 pg/mL for women and ≤20 pg/mL for men; weakly positive, 21-88 pg/mL for men and 16-88 pg/mL for women; and strongly positive, >88 pg/mL for men and women. A propensity score matching analysis was also conducted using the negative group as a control; the weakly and strongly positive groups were compared to the control across differing cardiology covariates. This study introduces novel cutoffs for high-sensitivity troponin I (Beckman Coulter assay, Beckman Coulter, Inc., Chaska Campus, 1000 Lake Hazeltine Drive, Chaska, Minnesota 55318).
Bacterial blight, a major disease in rice, poses a serious impact on rice production. In this study, a doubled haploid (DH) population derived from a cross between the introduced japonica cultivar 'Maybelle' and the indica landrace 'Baiyeqiu' was used to investigate the pathogenicity of four pathogen races causing bacterial blight. The results showed that the pathogenicity of all the pathogen races exhibited continuous, transgressive distribution in the DH population. Moreover, strong correlations existed between every two pathogen races, with the correlation coefficients ranging from 0.3 to 0.6. A total of 12 quantitative trait loci (QTLs) distributed on chromosomes 1, 2, 3, 5, 6, 7, 9, and 12 were detected for rice bacterial blight, explaining 4.95% to 16.05% of the phenotype. Among these QTLs, a major QTL located in the interval RM6024-RM163 on chromosome 5 was detected in three pathogen races. In addition, the pyramiding of the positive alleles can apparently improve the rice resistance to bacterial blight. This study is of great significance for broadening the genetic resources with resistance to bacterial blight in China.
Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to surgery and gastroenterology, and can be used in treatment of patients with acute gastroduodenal hemorrhage. For this purpose fibrogasteroduodenoscopy is performed. Additionally through endoscope canal to source of hemorrhage brought is double-lumen Teflon catheter, through which during 5-7 minutes flow insufflation with ozone-oxygen mixture with concentration 90-100 mg/l and rate of gas flow 250 l/min, is carried out. Excessive waste gas mixture is removed to destructor. ^ EFFECT: method allows to increase efficiency and safety of endoscopic hemostasis due to ensuring local anti-hypoxia and systemic antioxidant effect with introduction of said mixture in definite mode. ^ 4 tbl
Pregnant women (n:44) who participated in this group were administered inhalation with lavender oil at an intensity of at least 10 minutes in each phase during the first phase of labor. Visual Analog Pain Scale and McGill Melzack Pain Questionnaire were applied before and after the application, and the process was completed with a total of 6 measurements.
1. Technical Result Inhibiting formation of tumor necrosis factor (TNF).          2. Essence A compound of the formula wherein R1, R2 and R3 are disclosed in the description and pharmaceutical composition containing the same useful in the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders, etc.         3. Field of Application Medicine.
All participants in this arm will initially receive two additional sessions in which a workshop on PNE will be administered and discussed. A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
BACKGROUND AND AIMS: Sarcopenia is an important prognostic factor for cancer patients. The aim of this study was to assess the ability of sarcopenia to predict recurrent biliary obstruction (RBO) in patients with unresectable cancer after EUS-guided biliary drainage (EUS-BD).
METHODS: The study enrolled 113 patients who underwent EUS-BD using the self-expandable metal stent (SEMS) for unresectable malignant biliary obstruction (MBO) between April 2016 and December 2021 at Wakayama Medical University Hospital. The skeletal muscle index at the third lumbar spine level (L3) was calculated from computed tomography images. We analyzed the cumulative incidence of RBO at 180 days after stent insertion. Univariate and multivariate analyses were performed to identify variables significantly associated with RBO.
RESULTS: Seventy-six patients were assigned to the sarcopenia group, and 37 were assigned to the non-sarcopenia group. The 180-day cumulative incidence of RBO was 11% in the non-sarcopenia group and 29% in the sarcopenia group (p = 0.034). The time to RBO was significantly shorter for the sarcopenia group (p = 0.028; Gray's test). Multivariate analyses identified sarcopenia as an independent prognostic factor for RBO (present vs absent; HR 4.61; 95% CI 1.76-12.10, p = 0.001). The rates of biliary sludge/food impaction were significantly higher in the sarcopenia group for the causes of RBO (p = 0.048). There were no significant differences between the sarcopenia and the non-sarcopenia groups with respect to related EUS-BD adverse events.
CONCLUSION: Sarcopenia is an independent indicator of RBO in patients with MBO who receive EUS-BD with SEMS.
Benzene is a known contributor to human leukaemia through its toxic effects on bone marrow cells, and epigenetic modification is believed to be a potential mechanism underlying benzene pathogenesis. However, the specific roles of N6-methyladenosine (m6A), a newly discovered RNA post-transcriptional modification, in benzene-induced hematotoxicity remain unclear. In this study, we identified self-renewing malignant proliferating cells in the bone marrow of benzene-exposed mice through in vivo bone marrow transplantation experiments and Competitive Repopulation Assay. Subsequent analysis using whole transcriptome sequencing and RNA m6A methylation sequencing revealed a significant upregulation of RNA m6A modification levels in the benzene-exposed group. Moreover, RNA methyltransferase METTL14, known as a pivotal player in m6A modification, was found to be aberrantly overexpressed in Lin-Sca-1+c-Kit+ (LSK) cells of benzene-exposed mice. Further analysis based on the GEO database showed a positive correlation between the expression of METTL14, mTOR, and GFI and benzene exposure dose. In vitro cellular experiments, employing experiments such as western blot, q-PCR, m6A RIP, and CLIP, validated the regulatory role of METTL14 on mTOR and GFI1. Mechanistically, continuous damage inflicted by benzene exposure on bone marrow cells led to the overexpression of METTL14 in LSK cells, which, in turn, increased m6A modification on the target genes' (mTOR and GFI1) RNA. This upregulation of target gene expression activated signalling pathways such as mTOR-AKT, ultimately resulting in malignant proliferation of bone marrow cells. In conclusion, this study offers insights into potential early targets for benzene-induced haematologic malignant diseases and provides novel perspectives for more targeted preventive and therapeutic strategies.
PCT No. PCT/FR94/00307 Sec. 371 Date Nov. 13, 1995 Sec. 102(e) Date Nov. 13, 1995 PCT Filed Mar. 21, 1994 PCT Pub. No. WO94/21275 PCT Pub. Date Sep. 29, 1994A therapeutical composition for use in humans, comprising a combination of at least one natural or recombinant and preferably human cytokine with at least one muramyl peptide selected from those which, when administered in vivo together with an interferon, also induce an increased in vivo production of an interleukin-1 receptor antagonist IL-1 RA, but preferably do not induce any increase in TNF, IL-8 and IL-1 cytokines. Said composition is useful for antiviral and antitumoral therapies and/or for promoting restoration of the haematopoietic system, particularly in individuals with a weakened immune system.
The invention discloses a sodium bicarbonate injection and a preparation method thereof, wherein the pH value of the sodium bicarbonate injection is 8.7-9.5. At this PH, the composition of the components in the solution was: sodium carbonate: 1.62X 10 -2 mol/L~8.98×10 -2 mol/L, sodium bicarbonate: 0.505-0.581 mol/L; carbonic acid: 3.83X 10 -4 mol/L~2.76×10 -3 mol/L. Through further research, the sodium bicarbonate injection disclosed by the invention has better physical and chemical stability within the pH value range of 8.7-9.5And (5) performing qualitative determination. The preparation process does not need to add excessive CO 2 To maintain the product pH. It is effective in providing sufficient exogenous bicarbonate. It can be concluded that the side effects of hypercapnia caused by common sodium bicarbonate injection, aggravation of lactic acidosis caused by rapid acidification in cells, and the like can be reduced in the clinical application process.
In the preparation of assimilable calcium preparations according to the parent Specification the composition may be so modified that the proportion of the electric conductivity of the mixture due to calcium ions is increased up to one-half of the conductivity of an equivalent solution of the calcium compound in water, in the case of preparations of acid taste due to the inclusion of an acid or acid salt.  Such preparations, or those prepared according to the parent Specification may contain also non-assimilable ingredients such as latex, natural or synthetic rubber products, or chewing gum bases, such as that described in Specification 357,350.  According to one example the preparation contains calcium lactate 3 parts, citric acid 0,2 parts, gelatin 2 parts, sugar 4 parts and water 90,8 parts.  In the case of supersaturated solutions the proportion of colloids may be reduced, or they may be omitted.  Such a preparation may contain calcium lactate 10 parts, citric acid 1,5 parts, saccharose 58,5 parts, and water 30 parts.  The citric acid may be added after a solution of the other ingredients has been cooled, or the ingredients may be quickly dissolved together with heating, and the solution cooled and decanted from any citrate crystals that may have formed. Preparations in the form of oil-water or water-oil emulsions may also be employed.
PURPOSE: To obtain a pharmaceutical preparation having hypotensive activity and containing a potassium channel activating hypotensive agent and a β-blocker hypotensive agent. CONSTITUTION: The objective preparation is produced by mixing a potassium channel activating hypotensive agent and a βblocker hypotensive agent with a pharmacologically permissible additive and forming the mixture in the form of a drug by conventional method. It can be used in the form of tablet, capsule, peroral liquid agent, powder, granule, troche, injection, suspension, suppository, etc. The potassium channel activating hypotensive agent is pinacidil, RP49356 or a compound of the formula I [Y is N and R2 is H or Y is C-R1 (either one of R1 and R2 is H and the other is nitro, cyano, etc.); one of R3 and R4 is H or a l-4C alkyl and the other is a 1-4C alkyl, etc.; R5 is H, hydroxy, etc.; R6 is H, etc.; R7 is H, a 1-6C alkyl, etc.; R8 is H, a 1-6C alkyl, etc.; X is O or S; etc.] and the β-blocker hypotensive agent is a compound of the formula II, III or IV.
Schistosomiasis is one of the most devastating human diseases worldwide. The disease is caused by six species of Schistosoma blood fluke; five of which cause intestinal granulomatous inflammation and bleeding. The current diagnostic method is inaccurate and delayed, hence, biomarker identification using metabolomics has been applied. However, previous studies only investigated infection caused by one Schistosoma spp., leaving a gap in the use of biomarkers for other species. No study focused on understanding the progression of intestinal disease. Therefore, we aimed to identify early gut biomarkers of infection with three Schistosoma spp. and progression of intestinal pathology. We infected 3 groups of mice, 3 mice each, with Schistosoma mansoni, Schistosoma japonicum or Schistosoma mekongi and collected their feces before and 1, 2, 4 and 8 weeks after infection. Metabolites in feces were extracted and identified using mass spectrometer-based metabolomics. Metabolites were annotated and analyzed with XCMS bioinformatics tool and Metaboanalyst platform. From >36,000 features in all conditions, multivariate analysis found a distinct pattern at each time point for all species. Pathway analysis reported alteration of several lipid metabolism pathways as infection progressed. Disturbance of the glycosaminoglycan degradation pathway was found with the presence of parasite eggs, indicating involvement of this pathway in disease progression. Biomarkers were discovered using a combination of variable importance for projection score cut-off and receiver operating characteristic curve analysis. Five molecules met our criteria and were present in all three species: 25-hydroxyvitamin D2, 1α-hydroxy-2β-(3-hydroxypropoxy) vitamin D3, Ganoderic acid Md, unidentified feature with m/z 455.3483, and unidentified feature with m/z 456.3516. These molecules were proposed as trans-genus biomarkers of early schistosomiasis. Our findings provide evidence for disease progression in intestinal schistosomiasis and potential biomarkers, which could be beneficial for early detection of this disease.
Infectious diseases remain one of the leading causes of death worldwide despite innovations in medical research and the availability of new treatments. Emerging diseases include outbreaks of previously unknown diseases or known diseases where the incidence in humans has significantly increased in the past two decades. Detailed studies on emerging and re-emerging infectious agents to better understand pathogens' biology and host pathogenesis are mostly lacking. This study protocol is to prepare for a rapid coordinated clinical investigation of acute infections of emerging and re-emerging infectious agents in Mali. In collaboration with the Mali Ministry of Health and Public Hygiene, we will conduct an observational study to include participants with a spectrum of emerging or unknown pathogens with the objective to determine etiology and clinical characteristics of those diseases. Patients with suspected emerging or re-emerging infectious diseases within 15 km of Point G Hospital in Bamako will be invited to participate in this study.
A composition for preventing hair loss and promoting hair growth, which contains Magnolia officinalis Rehd. et Wils. extract or 4-Omethylhonokiol isolated from the extract is provided to suppress the activation of 5 alpha-reductase and improve the growth of hair follicle. A pharmaceutical or cosmetic composition for promoting hair growth and preventing hair loss comprises Magnolia officinalis Rehd. et Wils. extract. The pharmaceutical composition for promoting hair growth and preventing hair loss comprises a 4-Omethylhonokiol of the chemical formula 1 or its pharmaceutically acceptable salt as an active ingredient. The Magnolia officinalis Rehd. et Wils. extract is isolated using water, low alcohol of 1-4 carbon atoms or their mixture solvent, hexane, butylenes glycol, propylene glycol, glycerin, acetic acid ethyl, ether or chloroform. The pharmaceutical composition is used in the form of cream, gel, patch, spray, ointment, lotion, liniment, paste or cataplasma agent.
Prior to application of Tolak Cream, wash, rinse, and dry the treatment areas. Apply Tolak Cream once daily in an amount sufficient to cover the lesions of the face, ears, and/or scalp with a thin film, using the fingertips to gently massage the medication uniformly into the skin. Apply Tolak Cream for a period of 4 weeks as tolerated. Thoroughly wash hands following Tolak Cream application. 

Tolak Cream is for topical use only. Do not apply to eyes, nose, mouth or mucous membranes. Not for ophthalmic, oral or intravaginal use.
BACKGROUND: Falls represent a critical concern in Parkinson's disease (PD), contributing to increased morbidity and reduced quality of life.
PURPOSE: We conducted a systematic review to assess the prognostic factors associated with falls in PD, aiming to provide a comprehensive overview of relevant demographic and clinical parameters, and aid neurologists in identifying subsets of PD patients most susceptible to falls and associated injuries.
METHODS: PubMed and Web of Science databases were searched for prospective studies assessing factors associated with falls in ambulatory PD patients across different settings, from inception to August 2023. Data extraction was conducted using CHARMS-PF checklist and risk of bias was assessed with QUIPS tool. PRISMA guidelines were followed.
RESULTS: The initial search yielded 155 references. Thirty-four studies, involving a total of 3454 PD patients, were included in the final analysis. The mean pooled age was 67.6 years, and 45.1% were women. PD patients presented mild motor impairment (UPDRS III score 27.8) with mean pooled disease duration of 5.7 years. Gait and balance disorders and history of prior falls emerged as the most consistent predictors of falls across studies. Disease duration, disease severity, dysautonomic symptoms, freezing of gait, frontal cognitive functions, and PD medication dosages yielded inconsistent findings. Conversely, dyskinesias, age, sex, and depression were unrelated to future falls in PD. Logistic regression models were most commonly employed to identify factors significantly associated with falls in PD. Substantial heterogeneity prevailed in the inclusion of confounding factors.
CONCLUSION: The evidence suggests that previous history of falls, gait disorders, and poor balance are robust prognostic markers for falls in PD.
PURPOSE:To obtain the titled extremely flexible film, easily in a short time, by mixing a water-soluble polymer, a drug component, an additive and a plasticizer, compression molding the mixture to obtain a film, applying a solution of a water-soluble polymer containing an agent to make hardly water-soluble, to a  surface of the film, and curing the coating layer. CONSTITUTION:A water-soluble polymer (e.g. water-soluble cellulose derivative), a drug component, an additive (e.g. diluent, taste-improving agent, smell-improving agent, colorant, etc.), and if necessary a plasticizer (e.g. polyethylene glycol) are mixed together homogeneously, and compression molded to obtain a film. When a plasticizer is not added to the mixture, it is impregnated in the film. A surface of the film is coated with a solution of a water-soluble polymer containing an agent to make hardly water-soluble (e.g. shellac, higher fatty acid, etc.). The solvent is removed from the coating layer, and the coating is cured to obtain the titled film. A flexible film which scarcely gives undesirable feeling  to the mucous membrane can be prepared, continuously, in a short time, in  bulk, by the above process.